Lv3
270 积分 2022-05-26 加入
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
15小时前
待确认
Anti-Müllerian hormone and embryo quality as determined by time-lapse imaging
1个月前
已完结
Phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer (072)
5个月前
已完结
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer
5个月前
已完结
Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives
5个月前
已完结
CDK4/6 inhibitor dalpiciclib combined with non-steroidal aromatase inhibitors in estrogen receptor-positive recurrent/metastatic ovarian cancer and uterine neoplasms
5个月前
已完结
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
5个月前
已完结
安罗替尼对进展期放射性碘难治性分化型甲状腺癌的疗效及对病灶摄碘功能的影响
6个月前
已完结
The development of the pupillary light reflex and menace response in neonatal lambs and kids
6个月前
已完结
皖公网安备34019202002308
